These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21541661)

  • 1. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
    Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
    Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
    Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
    World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
    Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
    Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
    Ma Q; Qi C; Tie C; Guo Z
    Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis.
    Peng Q; Li S; Lao X; Chen Z; Li R; Qin X
    Medicine (Baltimore); 2014 Dec; 93(29):e330. PubMed ID: 25546681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
    Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
    Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.
    Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H
    Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis.
    Yuan H; Niu YM; Wang RX; Li HZ; Chen N
    Genet Mol Res; 2011 Nov; 10(4):3356-64. PubMed ID: 22179996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in XPD (Asp312Asn and Lys751Gln) genes, sunburn and arsenic-related skin lesions.
    McCarty KM; Smith TJ; Zhou W; Gonzalez E; Quamruzzaman Q; Rahman M; Mahiuddin G; Ryan L; Su L; Christiani DC
    Carcinogenesis; 2007 Aug; 28(8):1697-702. PubMed ID: 17470448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.
    Ding DP; Ma WL; He XF; Zhang Y
    Mol Biol Rep; 2012 Mar; 39(3):2533-40. PubMed ID: 21667112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
    Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
    Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis.
    Wang M; Gu D; Zhang Z; Zhou J; Zhang Z
    J Toxicol Environ Health A; 2009; 72(11-12):698-705. PubMed ID: 19492231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis.
    Li C; Jiang Z; Liu X
    Mol Biol Rep; 2010 Jan; 37(1):301-9. PubMed ID: 19669592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects.
    Zhang J; Qiu LX; Leaw SJ; Hu XC; Chang JH
    Med Oncol; 2011 Sep; 28(3):655-60. PubMed ID: 20354818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.
    Qiu LX; Yao L; Zhang J; Zhu XD; Zhao XM; Xue K; Mao C; Chen B; Zhan P; Yuan H; Hu XC
    Breast Cancer Res Treat; 2010 Nov; 124(1):229-35. PubMed ID: 20204500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer.
    Hansen RD; Sørensen M; Tjønneland A; Overvad K; Wallin H; Raaschou-Nielsen O; Vogel U
    Mutat Res; 2007 Jun; 619(1-2):68-80. PubMed ID: 17363013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XPD Lys751Gln polymorphisms and the risk of esophageal cancer: an updated meta-analysis.
    Guo XF; Wang J; Lei XF; Zeng YP; Dong WG
    Intern Med; 2015; 54(3):251-9. PubMed ID: 25748732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XPD Asp312Asn polymorphism is a risk factor for prostate cancer.
    Liao SG; Liu L; Wang Y; Zhang YY; Wang YJ
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1689-95. PubMed ID: 22644997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XPD Lys
    Yang QI; Wei YF; Zhang Y; Huang GM
    Exp Ther Med; 2015 Jun; 9(6):2406-2414. PubMed ID: 26136996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.
    Xue H; Lu Y; Lin B; Chen J; Tang F; Huang G
    PLoS One; 2012; 7(9):e43431. PubMed ID: 23028453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.